The official publication of the American College of Obstetricians and Gynecologists has endorsed the results of a clinical trial into HeraMED’s foetal monitoring device.

HeraMED (ASX:HMD) is a step closer to commercialisation following the endorsement of its tech by leading scientific journal ‘Obstetrics & Gynecology’.

The official publication of the American College of Obstetricians and Gynecologists found the HeraBEAT monitoring device to be “accurate and easy for clinicians and participants to use” and the data recorded “equivalent to those obtained using current assessment protocols for low-risk pregnancies, potentially allowing the device to be used in telehealth consultations”, further paving the path to commercialisation of the product.

Clinical success

HeraMED announced outstanding results from a clinical study with Joondalup Health Centre in 2020, finding that the HeraBEAT device detected a foetal heart rate on 100% of occasions by clinicians and, importantly, by expectant mothers using it without assistance.

Following this data, the peer-reviewed article in Obstetrics & Gynecology is expected to increase the awareness of the HeraCARE platform and HeraBEAT device, giving the company significant scientific credibility.

HeraMED anticipates the article will generate significant international exposure and underpin new partnership opportunities. The company is currently in a number of conversations with medical leaders and following the recent cooperation with Sheba Medical Centre (Sheba) in Israel (ASX announcement of 8 February 2021), HeraMED is now collaborating with two of the top 10 hospitals in the world – Mayo Clinic and Sheba.

More opportunities for growth

HeraMED CEO and co-founder, David Groberman, said the article provides an important connection for the company to leaders in the industry, providing another opportunity to further HeraMED’s growth strategy of forging key partnerships with global experts.

“I would like to congratulate Dr. Paul Porter and the research team for this publication which represents important scientific credibility for our technology. The publication of this article represents an endorsement of the 2020 JHC clinical study results and we are delighted that the outstanding results will now be brought to the attention of key opinion leaders globally, in the fields of obstetricians and gynaecologists,” said Groberman.

“Obstetrics & Gynecology represents one of the most highly cited journals, with an impact factor of 5.5, which places it in the top 7% of all scientific journals. Research for this journal undergoes an extremely rigorous peer review process and is considered the highest quality.

“This article, appearing in such a highly cited scientific journal, represents an important achievement for HeraMED and will represent an effective marketing tool as we continue to capitalise on the growing pipeline of new partnership opportunities.”

HeraMED’s HeraCARE cloud monitoring system and HeraBEAT smart foetal monitor operate on a SaaS model which provides hospitals and clinics with an alternative to expensive CTG machines which cannot be used for telehealth appointments.

The support of leading publications like Obstetrics & Gynecology furthers the ability of HeraMED to position its products as a viable alternative for medical professionals and allows the company to build its commercial partnerships and offer its flexible service for pre-natal care.

This article was developed in collaboration with HeraMED, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.